Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2021 Earnings Presentation
14 slides from Aft Pharmaceuticals's earnings presentation, November 2020
Slide 1: Investor Presentation November 2020
Working to improve your health INVESTOR PRESENTATION NOVEMBER 2020
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT for the financial year ended 31 March 2020. It is not prepared for any other purpose and must not be provided to any person other than the intended rec
Slide 3: H1 FY2021 financial highlights
H1 FY2021 financial highlights 21% Increase in number of countries Maxigesic sold in to 34 9% Increase in operating revenue from product sales to $48.4m 38% Decline in normalised operating profit to 1 (9% growth if adjusted for one off $1.7 million R&D credit in PY) $2.4m 968% Increase in normalised
Slide 4: Revenue Growth
Revenue Growth 11% 0% (16)% (7)% 53% product sales growth Investor presentation November 2020 4
Slide 5: Financial performance - revenue by region and channel
Financial performance - revenue by region and channel NZ$000's H1 H1 FY2020 FY2021 11% Australia 25,697 54.7% 28,552 58.5% 30% YoY growth 19.0% 11.1% 59% 29% New Zealand 13,691 29.2% 13,709 28.1% YoY growth 9.0% 0.1% 55% 16% Rest of World 5,189 11.1% 4,362 8.9% 3% YoY growth 64.4% -15.9% Product Sal
Slide 6: Abbreviated Consolidated Income Statement
Abbreviated Consolidated Income Statement NZ$'000's Half Year to 30 September H1 % of H1 % of FY2021 revenue FY2020 revenue Revenue 48,821 46,946 Gross Profit 20,332 41.6% 21,348 45.5% Underlying Operating Expenses and Other Income (17,910) (36.7%) (17,441) (37.2%) Underlying Operating Profit 2,422
Slide 7: Abbreviated Balance Sheet
Abbreviated Balance Sheet Unaudited Audited Unaudited NZ$'000's 30 Sept '20 31 March '20 30 Sept '19 Current assets 52,679 49,217 47,498 Cash and cash equivalents 5,870 6,119 7,308 Non-current assets 35,434 31,716 28,424 Total assets 93,983 87,052 83,230 Current liabilities 20,501 23,102 19,207 Curr
Slide 8: Cashflow
Cashflow H1 H1 NZ$'000's Half Year to 30 September FY2021 FY2020 Net cash from / (used in) operating activities (2,744) 6,135 Net cash used in investing activities (3,889) (2,770) Net cash from / (used in) financing activities 6,708 (2,778) Net increase in cash 75 587 Impact of foreign exchange on c
Slide 9: Normalised Operating profit progress
Normalised Operating profit progress NZ$ million 20 15 10 5 - '10 '11 '12 (5) '13 '14 '15 '16 '17 '18 '19 '20 '21 Investor presentation November 2020 (10) (15) 9
Slide 10: New Products build Revenue pipeline
New Products build Revenue pipeline Maxigesic o FDA CRL received for tablets indicating approvability after manufacturing site GMP audit o Maxigesic IV registrations successfully completed in 20 countries o Maxigesic Oral Liquid awaiting first registrations Maxigesic Hot Drink Sachets regulatory fil
Slide 11: Maxigesic Global Update
MAXIGESIC GLOBAL UPDATE [primarily oral dose forms] L i c e n s e d in R u s s i a Ireland – l a u n c h e d Singapore & Brunei – launched including O T C United K i n g d o m – l a u n c h e d C hina - licensing negotiations underw ay H o n g K o n g l a u n c h e d 2019 Nordics – launched L i c e
Slide 12: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered 120 100 80 60 40 105 7 orders 15 82 Investor presentation November 2020 20 orders 43 0 2 3 28 sold 4 20 FY14 7 9 sold FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 12
Slide 13: Maxigesic going forward
Maxigesic going forward Product Maxigesic Tablets Maxigesic IV Maxigesic oral solution Territories Sept March Sept March Sept March 2020 2020 2020 2020 2020 2020 Licensed 125+ 125+ -% 90 80 3% 122 122 -% Registered 46 44 5% 20 3 530% - - -% Sold in 34 28 20% 3 - +++% - - -% Investor presentation Nov
Slide 14: Outlook
Outlook Further Drive International Sales Keep accelerating number of new countries launched Launching new line extensions (e.g. Maxigesic IV) Extend International Licensing Finalise licensing agreement discussions in China, Japan, LATAM and USA Progress commercialisation in additional new t
AFT Pharmaceuticals — H1 FY2021 Earnings Presentation on 6ix